Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
3,237
Views
22
CrossRef citations to date
0
Altmetric
Back Matter

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Maria Georganakia Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Mohanraj Ramachandrana Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Sander Tuitb Genomics & Immunoregulation, Life and Medical Science Institute, University of Bonn, Bonn, GermanyView further author information
,
Nicolás Gonzalo Núñezc Institute of Experimental Immunology, University of Zurich, Zurich, SwitzerlandView further author information
,
Alexandros Karampatzakisa Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Grammatiki Fotakia Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Luuk van Hoorena Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Hua Huanga Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Roberta Luganoa Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Thomas Ulasb Genomics & Immunoregulation, Life and Medical Science Institute, University of Bonn, Bonn, GermanyORCID Iconhttps://orcid.org/0000-0002-9785-4197View further author information
ORCID Icon,
Aura Kaunistod Alligator Bioscience, Medicon Village, Lund, SwedenView further author information
,
Eric C Hollande Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Peter Ellmarkd Alligator Bioscience, Medicon Village, Lund, SwedenView further author information
,
Sara M Mangsbof Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Joachim Schultzeb Genomics & Immunoregulation, Life and Medical Science Institute, University of Bonn, Bonn, Germany;g Platform for Single Cell Genomics and Epigenomics, The German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn, Bonn, GermanyView further author information
,
Magnus Essanda Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenView further author information
,
Sonia Tuguesc Institute of Experimental Immunology, University of Zurich, Zurich, SwitzerlandView further author information
&
Anna Dimberga Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4422-9125View further author information
ORCID Icon show all
Article: 1730538 | Received 26 Jul 2019, Accepted 02 Dec 2019, Published online: 09 Mar 2020

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén & Peter Ellmark. (2021) Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy 21:12, pages 1635-1646.
Read now

Articles from other publishers (20)

Patrizia Leone, Eleonora Malerba, Nicola Susca, Elvira Favoino, Federico Perosa, Giuliano Brunori, Marcella Prete & Vito Racanelli. (2024) Endothelial cells in tumor microenvironment: insights and perspectives. Frontiers in Immunology 15.
Crossref
Andreas Fischer & Elisenda Alsina-Sanchis. (2024) Disturbed endothelial cell signaling in tumor progression and therapy resistance. Current Opinion in Cell Biology 86, pages 102287.
Crossref
Ada Nowosad, Jean-Christophe Marine & Panagiotis Karras. (2023) Perivascular niches: critical hubs in cancer evolution. Trends in Cancer 9:11, pages 897-910.
Crossref
Shilpi Singh, Debashis Barik, Ananta Prasad Arukha, Sujata Prasad, Iteeshree Mohapatra, Amar Singh & Gatikrushna Singh. (2023) Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment. Biomedicines 11:10, pages 2621.
Crossref
Jianwen Fang, Yue Lu, Jingyan Zheng, Xiaocong Jiang, Haixing Shen, Xi Shang, Yuexin Lu & Peifen Fu. (2023) Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death & Disease 14:9.
Crossref
Marit M Melssen, Natasha D Sheybani, Katie M Leick & Craig L SlingluffJrJr. (2023) Barriers to immune cell infiltration in tumors. Journal for ImmunoTherapy of Cancer 11:4, pages e006401.
Crossref
Juliana C.N. Kenski, Xinyao Huang, David W. Vredevoogd, Beaunelle de Bruijn, Joleen J.H. Traets, Sofía Ibáñez-Molero, Sebastiaan M. Schieven, Alex van Vliet, Oscar Krijgsman, Thomas Kuilman, Joanna Pozniak, Fabricio Loayza-Puch, Alexandra M. Terry, Judith Müller, Meike E.W. Logtenberg, Marjolein de Bruijn, Pierre Levy, Pierre-René Körner, Colin R. Goding, Ton N. Schumacher, Jean-Christophe Marine, Reuven Agami & Daniel S. Peeper. (2023) An adverse tumor-protective effect of IDO1 inhibition. Cell Reports Medicine 4:2, pages 100941.
Crossref
Elmira Roshani Asl, Davoud Rostamzadeh, Pascal H.G. Duijf, Sahar Mafi, Behnaz Mansoori, Shirin Barati, William C. Cho & Behzad Mansoori. (2023) Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe. Life Sciences 315, pages 121361.
Crossref
Maysaa Abdulla, Christer Sundström, Cecilia Lindskog & Peter Hollander. (2023) Expression of IDO1 and PD-L2 in Patients with Benign Lymphadenopathies and Association with Autoimmune Diseases. Biomolecules 13:2, pages 240.
Crossref
AP Abu Hejleh, K Huck, K Jähne, CL Tan, TV Lanz, L Epping, JK Sonner, SG Meuth, A Henneberg, CA Opitz, C Herold-Mende, F Sahm, M Platten & K Sahm. (2023) Endothelial Indoleamine-2,3-Dioxygenase-1 is not Critically Involved in Regulating Antitumor Immunity in the Central Nervous System. International Journal of Tryptophan Research 16, pages 117864692311531.
Crossref
Lothar C. Dieterich, Carlotta Tacconi, Luca Ducoli & Michael Detmar. (2022) Lymphatic vessels in cancer. Physiological Reviews 102:4, pages 1837-1879.
Crossref
Eslam E. Abd El-Fattah. (2022) IDO/kynurenine pathway in cancer: possible therapeutic approaches. Journal of Translational Medicine 20:1.
Crossref
Hua Huang, Maria Georganaki, Lei Liu Conze, Bàrbara Laviña, Luuk van Hooren, Kalyani Vemuri, Tiarne van de Walle, Mohanraj Ramachandran, Lei Zhang, Fredrik Pontén, Michael Bergqvist, Anja Smits, Christer Betsholtz, Elisabetta Dejana, Peetra U Magnusson, Liqun He, Roberta Lugano & Anna Dimberg. (2022) ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma. Neuro-Oncology 24:3, pages 398-411.
Crossref
Michael Welsh. (2022) Perspectives on Vascular Regulation of Mechanisms Controlling Selective Immune Cell Function in the Tumor Immune Response. International Journal of Molecular Sciences 23:4, pages 2313.
Crossref
Yu Yao, Heng Liang, Xin Fang, Shengnan Zhang, Zikang Xing, Lei Shi, Chunxiang Kuang, Barbara Seliger & Qing Yang. (2021) What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Rujia Qin, Wen Peng, Xuemin Wang, Chunyan Li, Yan Xi, Zhaoming Zhong & Chuanzheng Sun. (2021) Identification of Genes Related to Immune Infiltration in the Tumor Microenvironment of Cutaneous Melanoma. Frontiers in Oncology 11.
Crossref
Chan Mo, Shuwen Xie, Bin Liu, Weichao Zhong, Ting Zeng, Sha Huang, Yuqi Lai, Guanghui Deng, Chuying Zhou, Weixin Yan, Yuyao Chen, Shaohui Huang, Lei Gao & Zhiping Lv. (2021) Indoleamine 2,3-dioxygenase 1 limits hepatic inflammatory cells recruitment and promotes bile duct ligation-induced liver fibrosis. Cell Death & Disease 12:1.
Crossref
Antonio Giovanni Solimando, Simona De Summa, Angelo Vacca & Domenico Ribatti. (2020) Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers 12:11, pages 3380.
Crossref
Annabel Meireson, Michael Devos & Lieve Brochez. (2020) IDO Expression in Cancer: Different Compartment, Different Functionality?. Frontiers in Immunology 11.
Crossref
Laurenz Nagl, Lena Horvath, Andreas Pircher & Dominik Wolf. (2020) Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives. Frontiers in Cell and Developmental Biology 8.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.